Home
Scholarly Works
Secukinumab provides greater cumulative 52-week...
Conference

Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: An area under the curve analysis

Authors

Vender R; Leonardi C; Puig L; Ziv M; Zhao Y; Gilloteau I; McLeod L; Nyirady J; Guana A

Volume

76

Pagination

pp. AB231-AB231

Publisher

MOSBY-ELSEVIER

Publication Date

June 1, 2017

Name of conference

Annual Meeting of the American-Academy-of-Dermatology

Conference place

Orlando, FL

Conference start date

March 3, 2017

Conference end date

March 7, 2017

Conference proceedings

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Issue

6

ISSN

0190-9622

Labels

Fields of Research (FoR)

Contact the Experts team